The VM2 method, developed by VeraChem, calculates true free energies of binding using the mining minima method – a rigorous statistical mechanics based approach. VM2 can provide accurate protein-ligand binding affinities, and recent advances, such as parallel processor implementations for CPU and GPU clusters, as well as ports to Cloud platforms, now allow routine use of VM2 for rank-ordering of ligand series in pharmaceutical industry drug development settings.
Conventional drug lead optimization requires multiple rounds of intensive chemical synthesis and testing to make improvements in properties such as solubility while maintaining potency. Accurate predictions of protein-ligand binding affinities, therefore, provide the potential for tremendous savings with respect to cost and time in the drug development process.
If you think VM2 can help in your drug development efforts contact us at vc@verachem.com or submit a request to get VM2 below.